← The Wire
DMRANasdaq
Damora Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1800315
Damora Therapeutics develops biologics to treat mutant calreticulin-driven blood disorders
red 8-K · 90d
$1.28B
Market cap
$24.21
Last close
-4.5%
1D
+1.4%
5D
523K
Volume
Price · last 39 sessions-6.6%
May 4L $20.07 · H $25.93Jun 29
90
Total filings
Jun 17, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 17, 202610-Q10-QMay 12, 20268-KExecutive ChangeMay 4, 2026DEF 14ADEF 14AApr 29, 2026DEFA14ADEFA14AApr 29, 20268-KAuditor ChangeApr 20, 20268-KExecutive Change · Reg FD DisclosureMar 23, 202610-K10-KMar 19, 20268-KResults of Operations · Bylaw AmendmentMar 10, 20268-KMaterial AgreementFeb 11, 2026424B5424B5Feb 11, 2026SC 13D/ASC 13D/AFeb 11, 2026424B5424B5Feb 10, 20268-KExecutive Change · Bylaw AmendmentFeb 10, 20268-KReg FD DisclosureJan 12, 20268-KExecutive Change · Equity IssuanceJan 6, 2026DEF 14ADEF 14ADec 31, 20258-K/ABylaw AmendmentDec 9, 20258-KExecutive Change · Material AgreementNov 10, 202510-Q10-QNov 6, 202510-Q10-QAug 5, 20258-KShareholder VoteJun 20, 202510-Q10-QMay 8, 2025DEFA14ADEFA14AApr 30, 2025DEF 14ADEF 14AApr 30, 202510-K10-KMar 19, 2025SC 13GSC 13GNov 7, 202410-Q10-QNov 1, 20248-KExecutive ChangeOct 15, 20248-KExecutive Change · Material AgreementOct 7, 20248-KCompany UpdateSep 18, 20248-KCompany UpdateSep 11, 20248-KBylaw AmendmentSep 5, 202410-Q10-QAug 12, 20248-KShareholder VoteJun 21, 202410-Q10-QApr 29, 2024DEF 14ADEF 14AApr 29, 20248-KCompany UpdateMar 26, 202410-K10-KMar 8, 20248-KCompany UpdateDec 21, 202310-Q10-QNov 6, 20238-KCompany UpdateOct 23, 2023SC 13GGALECTO13GOct 3, 20238-KDelisting NoticeOct 2, 20238-KExecutive Change · Exit / Disposal CostsSep 26, 20238-KReg FD Disclosure · Company UpdateAug 15, 202310-Q10-QJul 31, 20238-KShareholder VoteJun 15, 2023DEFA14ADEFA14AApr 28, 2023DEF 14ADEF 14AApr 28, 202310-Q10-QApr 28, 20238-KReg FD DisclosureMar 10, 2023424B5424B5Mar 9, 202310-K10-KMar 9, 20238-KResults of Operations · Reg FD DisclosureJan 6, 202310-Q10-QNov 8, 20228-KReg FD DisclosureOct 31, 20228-KReg FD Disclosure · Company UpdateSep 29, 202210-Q10-QJul 29, 20228-KShareholder VoteJun 17, 202210-Q10-QApr 29, 2022DEFA14ADEFA14AApr 28, 2022DEF 14ADEF 14AApr 28, 2022424B5424B5Feb 18, 202210-K10-KFeb 17, 20228-KExecutive ChangeFeb 9, 20228-KCompany UpdateJan 27, 20228-KReg FD DisclosureJan 5, 202210-Q10-QNov 4, 202110-Q10-QAug 5, 20218-KExecutive ChangeJul 6, 20218-KShareholder VoteMay 28, 202110-Q10-QMay 4, 2021DEFA14ADEFA14AApr 14, 2021DEF 14ADEF 14AApr 14, 202110-K10-KMar 29, 20218-KReg FD DisclosureMar 15, 2021SC 13GSC 13GFeb 12, 2021SC 13GJANUS HENDERSON GROUP PLC OWNS >5%Feb 12, 20218-KExecutive ChangeJan 8, 2021
Insider Activity
In the 90 days to Jan 2, 2026: 3 sold $23K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 2, 2026 | Schambye Hans T.Chief Executive Officer | Sell | 700 | $21.38 | $15K |
| Jan 2, 2026 | Winslow GarrettGeneral Counsel | Sell | 255 | $21.38 | $5K |
| Jan 2, 2026 | Firmani LoriChief Financial Officer | Sell | 135 | $21.41 | $3K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance